
Synthroid is owned by AbbVie Inc. (NYSE: ABBV), which inherited the brand through Abbott Laboratories' 2001 acquisition of Knoll Pharmaceuticals and kept it when AbbVie separated from Abbott in 2013. First marketed by Flint Laboratories in 1955, Synthroid was the first synthetic levothyroxine and remains one of the most prescribed medications in the United States.
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Synthroid | AbbVie Inc. | Product line |
Synthroid was the first synthetic thyroxine product marketed in the United States. Flint Laboratories, a division of Baxter Travenol, introduced it in 1955, shortly after chemists at Glaxo in the UK synthesized levothyroxine. The product replaced the desiccated animal thyroid extract that had been standard hypothyroidism treatment since the 1890s, offering consistent dosing the animal product could not match.
For its first decades, Synthroid had the market effectively to itself. It received no patent protection, yet no rival mounted a serious challenge, and by the 1980s Synthroid was among the most prescribed drugs in the country.
Corporate ownership turned over repeatedly. Boots acquired Flint in the 1980s. In 1995, Knoll Pharmaceuticals, then the pharmaceutical arm of German chemical group BASF, bought Boots' drug business and took Synthroid with it. In 2001, Abbott Laboratories bought Knoll for about $6.9 billion.
Two regulatory episodes define the modern history. For decades levothyroxine products were marketed without formal FDA approval under pre-1962 grandfathering. In 1997, the FDA declared all oral levothyroxine products new drugs requiring an approved application. Abbott filed its NDA and received approval in July 2002, making Synthroid an approved drug nearly half a century after launch. Separately, the FDA ordered Abbott in 2001 to phase down distribution of its then-unapproved supply while the application was pending, one of the more unusual enforcement actions against a top-selling drug.
The 1990s also produced the brand's most cited scandal. Flint and later Knoll had funded a University of California, San Francisco study led by pharmacologist Betty Dong comparing Synthroid's bioequivalence to rivals. When the results showed no meaningful difference, Knoll moved to suppress publication. The paper finally appeared in JAMA in 1997, and the episode became a standard case study in industry interference with academic research. Knoll and Abbott later paid to settle related class action claims.
When Abbott split in two in January 2013, the research-based drug business became AbbVie, and Synthroid transferred to the new company. In 2020, AbbVie acquired Allergan for approximately $63 billion, uniting Synthroid with Armour Thyroid under one owner for the first time.
What does AbbVie own?
AbbVie owns a portfolio of prescription drug brands including Skyrizi, Rinvoq, Humira, Imbruvica, Venclexta, Vraylar, Ubrelvy, Qulipta, and Elahere, plus the aesthetics products Botox Cosmetic and Juvederm acquired through the 2020 Allergan deal. All are internally held product brands rather than separate subsidiaries.
Is AbbVie publicly traded?
Yes. AbbVie trades on the New York Stock Exchange under ticker ABBV and is a component of the S&P 500. It has traded publicly since its January 2013 spin-off from Abbott Laboratories, and Abbott retains no ownership stake.
Who founded AbbVie?
AbbVie was not founded by individuals but created as a corporate spin-off from Abbott Laboratories in 2013, led at launch by CEO Richard A. Gonzalez. Its operating heritage traces to Dr. Wallace C. Abbott, who founded Abbott's predecessor drug company in Chicago in 1888.
Where is AbbVie headquartered?
AbbVie is headquartered in North Chicago, Illinois, in the same suburban Chicago corridor where Abbott has long been based. Its principal offices sit at 1 North Waukegan Road.
How many brands does AbbVie own?
AbbVie markets roughly a dozen major product brands, led by Skyrizi, Rinvoq, Humira, Botox, Juvederm, Imbruvica, and Venclexta, plus smaller products across eye care and neuroscience. Unlike consumer conglomerates, its brands are individual prescription medicines rather than retail labels.
Who owns AbbVie?
AbbVie is owned by public shareholders, with Vanguard, BlackRock, and State Street as the largest institutional holders. Robert A. Michael serves as chairman and chief executive officer. No founding family or single shareholder controls the company.
What happened to Humira?
U.S. biosimilar competitors launched in January 2023 after AbbVie's patent settlements allowed entry. Humira worldwide revenue fell from a $21.2 billion peak in 2022 to $4.54 billion in 2025, while Skyrizi and Rinvoq grew to replace it, pushing total company revenue to a record $61.16 billion.
The brand's defining controversy is the Dong study suppression of the 1990s, detailed above: sponsor-funded research showing bioequivalence with cheaper products was withheld for years before appearing in JAMA in 1997. Knoll settled a related consumer class action, and the episode is still cited in discussions of pharmaceutical industry influence on research.
Regulatory friction continued into the 2000s. The FDA's 2001 order that Abbott phase down distribution of unapproved Synthroid was a rare enforcement step against a top-three selling drug, resolved when the NDA was approved in 2002.
Like all narrow therapeutic index drugs, Synthroid has also been subject to periodic potency and stability scrutiny. Patients and endocrinologists monitor reported variability between lots and between branded and generic products, and professional guidelines stress consistency of product for stable patients.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Pfizer | USA | 2001 | Mass market | United states | All Genders | |
| Amneal Pharmaceuticals | USA | 2000 | Mass market | United states | All Genders | |
| Abbvie | USA | 1900 | Mass market | United states | All Genders | |
| Ibsa | Switzerland | 2006 | Premium | United states | All Genders | |
| Ibsa | Switzerland | 2016 | Mass market | United states | All Genders |
Healthcare PharmaceuticalsOwned by Pfizer Inc.
Pfizer's levothyroxine brand for hypothyroidism, FDA approved in 2001 and inherited through the 2011 King Pharmaceuticals acquisition.
Healthcare PharmaceuticalsOwned by Amneal Pharmaceuticals, Inc.
Levothyroxine tablet for hypothyroidism, the first FDA-approved levothyroxine product, manufactured by Jerome Stevens Pharmaceuticals and distributed by Amneal.
Healthcare PharmaceuticalsOwned by AbbVie Inc.
AbbVie's natural desiccated thyroid brand derived from porcine thyroid glands, used for hypothyroidism for more than a century and acquired through Forest, Actavis, and Allergan.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Pharma's liquid levothyroxine oral solution, the first and only FDA-approved liquid levothyroxine, marketed in monodose ampules for hypothyroidism since 2019 in the US.
Market Positioning: Synthroid competes with 5 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by AbbVie Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
Tirosint is privately owned, unlike Synthroid which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Pharma's liquid levothyroxine oral solution, the first and only FDA-approved liquid levothyroxine, marketed in monodose ampules for hypothyroidism since 2019 in the US.
Tirosint-SOL is privately owned, unlike Synthroid which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by TTAM Research Institute
Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.
23andMe is privately owned, unlike Synthroid which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Adcock Ingram Holdings Limited
South African pharmaceutical brand behind Panado and Myprodol, now privately held by Bidvest and NATCO Pharma.
Adcock Ingram is privately owned, unlike Synthroid which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Global Medical Response
America's largest air ambulance membership network, covering more than 3 million members across 38 states, operated by Global Medical Response.
AirMedCare Network is privately owned, unlike Synthroid which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Alfa-Pharm CJSC
Armenia's largest pharmaceutical distributor and pharmacy chain, importing medicines from more than 70 global manufacturers since 1996.
Alfa-Pharm is privately owned, unlike Synthroid which is under a publicly traded parent company.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.